KW 7158
Latest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Kyowa Hakko
- Developer Kyowa Hakko; Kyowa Hakko Kirin
- Class Benzothiepins; Small molecules
- Mechanism of Action Potassium channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Irritable bowel syndrome; Overactive bladder
Most Recent Events
- 01 Oct 2008 Kirin Pharma Company has merged with Kyowa Hakko to form Kyowa Hakko Kirin
- 28 Jun 2005 Kyowa Hakko has completed phase IIa trials in urinary incontinence in the US and Europe
- 11 May 2005 Phase-II clinical trials in Overactive bladder in Japan (PO)